In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Top M&A Of 2016: Cast Your Vote!

Executive Summary

It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

In Vivo's Top M&A Of 2016 – The Nominees Are

A Big Year For NASH: Allergan built anon-alcoholic steatohepatitis franchise overnight in mid-September, acquiring Tobira Therapeutics for $1.7 billion and Akarna Therapeutics for $50 million. In April, Gilead Sciences paid $400 million up front plus earn-outs for its fourth NASH project, Nimbus Apollo and its Phase II-ready ACC inhibitor for NASH. [See Deal][See Deal]

LabCorp Strengthens Women's Health Offering With Sequenom Buy: In July,LabCorp of America announced its intent to acquire noninvasive prenatal testing specialist Sequenom in an all-cash deal. The transaction enables LabCorp to broaden its test offerings in women's health and expand its geographic reach, among other things. [See Deal]

Pfizer Prevails In Medivation Bidding War: In the biggest pharma M&A deal of the year to date, Pfizer bested multiple competitors with a $14 billion in August bid for the prostate cancer drug developer, showing just how far big pharmas are willing to go to compete in oncology. [See Deal]

Abbott Buys St. Jude For $25 billion: This April deal was the biggest medtech acquisition of the year, and created huge consolidation in the cardiovascular device market. [See Deal]

QuintilesIMS: Big Merger In Big Data: CRO Quintiles merged with health care data giant IMS Health in May in a deal worth $9 billion. QuintilesIMS will have a market cap close to $18 billion, not to mention a huge head start in finding real-world evidence solutions for clients.

CLICK HERE To Cast Your Vote For The Most Significant M&A Of 2016

CLICK HERE To Cast Your Vote For The Most Significant Financing Of 2016

CLICK HERE to Cast Your Vote For The Most Significant Strategic Alliance Of 2016

Related Content


Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts